Literature DB >> 2446690

Quantitative assessment of lung damage due to bleomycin using computed tomography.

E A Bellamy1, D Nicholas, J E Husband.   

Abstract

Visual assessment and density measurements of the lung using computed tomography (CT) were made in 18 patients undergoing treatment with bleomycin for malignant teratoma of the testis. The results of both visual assessment and density measurements were compared with changes in gas transfer per unit lung volume (KCO). Visual assessment of severity of damage to the lungs caused by bleomycin is unrelated to changes in KCO but is characteristic of bleomycin damage and allows a confident diagnosis to be made. Quantitative density measurement by CT, however, is inversely related to changes in KCO and may therefore be used to monitor the physiological effect on the patient. Examination of the lung by CT in these patients can not only characterise and define the extent of lung damage due to bleomycin but can be used to give a quantitative measurement on which to monitor treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446690     DOI: 10.1259/0007-1285-60-720-1205

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  3 in total

1.  Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.

Authors:  Martha W den Hollander; Nico-Derk L Westerink; Sjoukje Lubberts; Alfons H H Bongaerts; Rienhart F E Wolf; Renska Altena; Janine Nuver; Sjoukje F Oosting; Elisabeth G E de Vries; Anna M E Walenkamp; Coby Meijer; Jourik A Gietema
Journal:  Oncologist       Date:  2016-06-21

2.  High resolution pulmonary computed tomography scans quantified by analysis of density distribution: application to asbestosis.

Authors:  D Eterović; Z Dujić; J Tocilj; V Capkun
Journal:  Br J Ind Med       Date:  1993-06

3.  Bleomycin lung: the effect of different chemotherapeutic regimens.

Authors:  R A Chisholm; A K Dixon; M V Williams; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.